Gwenaelle Gravis

Identifiants chercheurs

IdHAL :

gwenaelle-gravis

ORCID :

0000-0002-3127-1554

ResearcherID :

http://www.researcherid.com/rid/CAG-3019-2022

Présentation

Publications

Article dans une revue (95)

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study Ronan Flippot,Yann-Alexandre Vano,Cécile Dalban,Benoit Beuselinck,Aude Fléchonet al. European Urology, 2026, ⟨10.1016/j.eururo.2025.09.4169⟩ Article dans une revue hal-05423521v1
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial L. Bergmann,L. Albiges,M. Ahrens,M. Gross-Goupil,E. Boletiet al. Annals of Oncology, 2025, 36 (7), pp.796-806. ⟨10.1016/j.annonc.2025.03.016⟩ Article dans une revue hal-05592634v1
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial Ronac Mamtani,Nobuaki Matsubara,Alvaro Montesa Pino,Urbano Anido Herranz,Gwenaelle Graviset al. Clinical Genitourinary Cancer, 2025, 23 (1), pp.102248. ⟨10.1016/j.clgc.2024.102248⟩ Article dans une revue hal-05148403v1
Improving transparency and empowerment for cancer patients by accessing their full online personal medical records Gwenaelle Gravis,Rajae Touzani,Thérèse Aurran,Aude Charbonnier,Domitille Danoet al. Supportive Care in Cancer, 2025, 33, pp.656. ⟨10.1007/s00520-025-09729-7⟩ Article dans une revue hal-05592982v1
Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial. Nadine Houédé,Thierry Chevallier,François Audenet,Constance Thibault,Yann Neuzilletet al. Journal of Clinical Oncology, 2025, 43 (13), pp.578-1586. ⟨10.1200/jco-25-00179⟩ Article dans une revue hal-05314103v1
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial Adrien Rousseau,Maryam Karimi,Stefan Michiels,Guilhem Roubaud,Xavier Maldonadoet al. European Journal of Cancer, 2025, 230, pp.116024. ⟨10.1016/j.ejca.2025.116024⟩ Article dans une revue inserm-05382223v1
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand? Arthur Géraud,Paul Gougis,Alexandre de Nonneville,Mathilde Beaufils,François Bertucciet al. Cancer Treatment Reviews, 2025, 135, pp.102922. ⟨10.1016/j.ctrv.2025.102922⟩ Article dans une revue hal-05240065v1
BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells Emilien Billon,Caroline Imbert,Damien Bruyat,Pierre Grassi,Lucie Robertet al. Cell Reports, 2025, 44 (10), pp.116387. ⟨10.1016/j.celrep.2025.116387⟩ Article dans une revue hal-05577986v1
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up J. Walz,G. Attard,A. Bjartell,P. Blanchard,E. Castroet al. Annals of Oncology, 2025, pp.S0923-7534(25)06330-6. ⟨10.1016/j.annonc.2025.12.009⟩ Article dans une revue inserm-05435189v1
Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. Nadine Houede,Thierry Chevallier,Jaffrelot Loic,Constance Thibault,Neuzillet Yannet al. Journal of Clinical Oncology, 2025, 43 (5_suppl), pp.661-661. ⟨10.1200/jco.2025.43.5_suppl.661⟩ Article dans une revue hal-05033783v1
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 Neeraj Agarwal,Daniel Castellano,Teresa Alonso-Gordoa,Jose Angel Arranz Arija,Emeline Colombaet al. Clinical Cancer Research, 2024, 30 (11), pp.2377-2383. ⟨10.1158/1078-0432.CCR-23-3436⟩ Article dans une revue hal-05148434v1
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab Matthew Milowsky,Peter O'Donnell,Christopher Hoimes,Daniel Petrylak,Thomas Flaiget al. Journal of Clinical Oncology, 2024, 42 (12), pp.1403-1414. ⟨10.1200/JCO.23.01547⟩ Article dans une revue hal-05148455v1
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203) A.M. Di Giacomo,M. Schenker,J. Medioni,S. Mandziuk,M. Majemet al. ESMO Open, 2024, 9 (3), pp.102387. ⟨10.1016/j.esmoop.2024.102387⟩ Article dans une revue hal-05141645v1
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort Jeremie Naffrichoux,Pierre Poupin,William Pouillot,Claude Linassier,Nathalie Rioux-Leclercqet al. European Journal of Cancer, 2024, 205, pp.114121. ⟨10.1016/j.ejca.2024.114121⟩ Article dans une revue hal-04615732v1
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study Evan Yu,William Berry,Howard Gurney,Margitta Retz,Henry Conteret al. European Urology Oncology, 2024, 7 (3), pp.509-518. ⟨10.1016/j.euo.2023.10.008⟩ Article dans une revue hal-05148411v1
Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] Matthew Galsky,Dean Bajorin,Johannes Alfred Witjes,Jürgen Gschwend,Yoshihiko Tomitaet al. European Urology, 2024, 85 (3), pp.e96-e97. ⟨10.1016/j.eururo.2023.12.013⟩ Article dans une revue hal-05148414v1
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study F. Carneiro,A. Vinceneux,M. Larroquette,M. Rony,L. Carrilet al. European Journal of Cancer, 2024, 199, pp.113534. ⟨10.1016/j.ejca.2024.113534⟩ Article dans une revue hal-05148404v1
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. Mathilde Cancel,Jérémie Naffrichoux,Pierre Poupin,William Pouillot,Claude Linassieret al. Journal of Clinical Oncology, 2024, 42 (4_suppl), pp.463. ⟨10.1200/JCO.2024.42.4_suppl.463⟩ Article dans une revue hal-05148453v1
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study Gwenaelle Gravis,Patricia Marino,Daniel Olive,Frederique Penault-Llorca,Jean-Pierre Delordet al. BMC Cancer, 2023, 23 (1), pp.393. ⟨10.1186/s12885-023-10881-8⟩ Article dans une revue hal-04109560v1
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial Stéphane Culine,Valentin Harter,Clémentine Krucker,Gwénaëlle Gravis,Aude Fléchonet al. Cancers, 2023, 15 (6), pp.1742. ⟨10.3390/cancers15061742⟩ Article dans une revue hal-04195179v1
Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide Lucie-Marie Scailteux,Sebastien Vincendeau,Gwenaelle Gravis,Romain Mathieu,Frederic Balussonet al. Clinical Genitourinary Cancer, 2023, 21 (5), pp.e362-e369. ⟨10.1016/j.clgc.2023.04.004⟩ Article dans une revue hal-04121016v1
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma Manon de Vries-Brilland,Nathalie Rioux-Leclercq,Maxime Meylan,Jonathan Dauvé,Christophe Passotet al. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩ Article dans une revue hal-04341909v1
Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial Valentina Orlando,Damien Drubay,Pernelle Lavaud,Laura Faivre,François Lesaunieret al. Clinical Genitourinary Cancer, 2023, 21 (5), pp.615.e1-615.e8. ⟨10.1016/j.clgc.2023.05.003⟩ Article dans une revue hal-04334564v1
Impact of active surveillance for prostate cancer on the risk of depression and anxiety Davidson Sypre,Géraldine Pignot,Rajae Touzani,Patricia Marino,Jochen Walzet al. Scientific Reports, 2022, 12 (1), pp.12889. ⟨10.1038/s41598-022-17224-w⟩ Article dans une revue inserm-04048149v1
Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN Géraldine Pignot,Rajae Touzani,Marc-Karim Bendiane,Julien Mancini,Jochen Walzet al. Future Oncology, 2022, 18 (14), pp.1733-1744. ⟨10.2217/fon-2021-1420⟩ Article dans une revue inserm-04039329v1
Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? Steven Tisseverasinghe,Marwan Tolba,Fred Saad,Gwenaelle Gravis,Boris Bahoricet al. Journal of Clinical Oncology, 2022, 40 (36), pp.4173+. ⟨10.1200/JCO.22.00883⟩ Article dans une revue hal-04084956v1
Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer Anne-Gaëlle Goubet,Leonardo Lordello,Carolina Alves Costa Silva,Isabelle Peguillet,Marianne Gazzanoet al. Cancer Discovery, 2022, 12 (10), pp.2280-2307. ⟨10.1158/2159-8290.CD-22-0201⟩ Article dans une revue hal-03951702v1
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma Lucie Meynard,Derek Dinart,Blandine Delaunay,Aude Flechon,Carolina Saldanaet al. European Journal of Cancer, 2022, 175, pp.43-53. ⟨10.1016/j.ejca.2022.08.014⟩ Article dans une revue hal-03836416v1
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Yann-Alexandre Vano,Réza Elaidi,Mostefa Bennamoun,Christine Chevreau,Delphine Borchielliniet al. Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩ Article dans une revue hal-04072026v1
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial Émilien Billon,Gwenaelle Gravis,Arnaud Guille,Nadine Carbuccia,José Adélaïdeet al. Cancers, 2022, 14 (9), ⟨10.3390/cancers14092275⟩ Article dans une revue hal-04085310v1
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study Yann‐alexandre Vano,Letuan Phan,Gwenaelle Gravis,Iphigénie Korakis,Friederike Schlürmannet al. International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩ Article dans une revue hal-04085018v1
The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey Patricia Marino,Rajae Touzani,Jihane Pakradouni,Patrick Ben Soussan,Gwenaelle Gravis Cancers, 2022, 14 (7), pp.1794. ⟨10.3390/cancers14071794⟩ Article dans une revue inserm-04042655v1
Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma Emilien Billon,Brice Chanez,Philippe Rochigneux,Laurence Albiges,Cécile Vicieret al. Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.670827⟩ Article dans une revue hal-03623028v1
Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review Maelle Rony,Jean-Philippe Ratone,Jochen Walz,Geraldine Pignot,Fabrice Caillolet al. Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.710477⟩ Article dans une revue hal-03623373v1
L’annonce du cancer au diagnostic de Tumeur de vessie non infiltrant le muscle modifie-t-elle la qualité de vie et l’observance des patients ? Données de la cohorte prospective française VICAN J Campagna,R Touzani,G Gravis,P Marino,J Walzet al. Progrès en Urologie, 2021, S1166-7087 (21), pp.00213-X. ⟨10.1016/j.purol.2021.08.035⟩ Article dans une revue inserm-03462183v1
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial François Bertucci,Anthony Gonçalves,Arnaud Guille,José Adelaïde,Séverine Garnieret al. Genome Medicine, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩ Article dans une revue hal-03583277v1
Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care Patricia Marino,Rajae Touzani,Lorène Seguin,Jean Francois Moulin,Myriam Palomareset al. Cancers, 2021, 13 (6), pp.1337. ⟨10.3390/cancers13061337⟩ Article dans une revue inserm-03462202v1
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial T.K. Choueiri,J. Larkin,S. Pal,R.J. Motzer,B.I. Riniet al. ESMO Open, 2021, 6 (3), pp.100101. ⟨10.1016/j.esmoop.2021.100101⟩ Article dans une revue hal-03623572v1
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET Gwenaelle Gravis,Aurélie Autret,Morgane Guibert-Broudic,Thomas Dubergé,Christophe Zemmouret al. Clinical Genitourinary Cancer, 2021, 19 (4), pp.346-353. ⟨10.1016/j.clgc.2021.03.004⟩ Article dans une revue hal-03623562v1
Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review Maelle Rony,Jean-Philippe Ratone,Jochen Walz,Geraldine Pignot,Fabrice Caillolet al. Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.644301⟩ Article dans une revue hal-03623317v1
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial Stéphane Culine,Valentin Harter,Gwenaelle Gravis,Aude Fléchon,Christine Chevreauet al. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩ Article dans une revue hal-03625944v1
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study Stéphane Culine,Aude Fléchon,Gwenaelle Gravis,Guilhem Roubaud,Yohann Loriotet al. Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩ Article dans une revue hal-03631553v1
Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’ T.K. Choueiri,J. Larkin,S. Pal,R.J. Motzer,B.I. Riniet al. ESMO Open, 2021, 6 (4), pp.100177. ⟨10.1016/j.esmoop.2021.100177⟩ Article dans une revue hal-03623494v1
Feasibility and first results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis. Geraldine Pignot,Marion Picini,Patricia Marino,Naji Salem,Stanislas Rybikowskiet al. Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.12071-12071. ⟨10.1200/JCO.2021.39.15_suppl.12071⟩ Article dans une revue hal-03623123v1
Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors Christine Chevreau,Christophe Massard,Aude Flechon,Rémy Delva,Gwenaëlle Graviset al. Cancer Medicine, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩ Article dans une revue hal-03208728v1
1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic G. Gravis Mescam,R. Touzani,J. Pakradouni,P. Bens Soussan,P. Marino Annals of Oncology, 2021, 32, pp.S1160. ⟨10.1016/j.annonc.2021.08.1635⟩ Article dans une revue inserm-03667002v1
665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101 M-O. Grimm,M. Oya,T.K. Choueiri,M. Schmidinger,D.I. Quinnet al. Annals of Oncology, 2021, 32, pp.S690-S691. ⟨10.1016/j.annonc.2021.08.061⟩ Article dans une revue hal-03623392v1
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer Rémi Pelloux-Prayer,Philomène Schiele,Stéphane Oudard,Gwenaëlle Gravis,François Kleinclausset al. Clinical Genitourinary Cancer, 2021, 19 (5), pp.e326-e333. ⟨10.1016/j.clgc.2021.03.022⟩ Article dans une revue hal-03612906v1
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales) Mathilde Cancel,Gaelle Fromont,Cyriac Blonz,Christine Chevreau,Nathalie Rioux-Leclercqet al. European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩ Article dans une revue hal-04242387v1
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? Arnaud Méjean,Alain Ravaud,Simon Thezenas,Christine Chevreau,Karim Bensalahet al. European Urology, 2021, 80 (4), pp.417-424. ⟨10.1016/j.eururo.2021.06.009⟩ Article dans une revue hal-03345230v1
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial Bernadett Szabados,Alejo Rodriguez-Vida,Ignacio Durán,Simon Crabb,Michiel van Der Heijdenet al. European Urology Oncology, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩ Article dans une revue hal-03623603v1
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program Laurence Albiges,Aude Fléchon,Christine Chevreau,Delphine Topart,Gwenaëlle Graviset al. European Journal of Cancer, 2021, 142, pp.102-111. ⟨10.1016/j.ejca.2020.09.030⟩ Article dans une revue hal-03623382v1
Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study Brice Chanez,Fabrice Caillol,Jean-Philippe Ratone,Christian Pesenti,Philippe Rochigneuxet al. Cancers, 2021, 13 (21), pp.5267. ⟨10.3390/cancers13215267⟩ Article dans une revue hal-03689914v1
Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort. Geraldine Pignot,Rajae Touzani,Patricia Marino,Jochen Walz,Stanislas Rybikowskiet al. Journal of Clinical Oncology, 2021, 39 (6SUPPL), pp.220-220. ⟨10.1200/JCO.2021.39.6_suppl.220⟩ Article dans une revue inserm-03665171v1
Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203). Michele Maio,Michael Schenker,Jacques Medioni,Slawomir Mandziuk,Margarita Majemet al. Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.2571-2571. ⟨10.1200/JCO.2021.39.15_suppl.2571⟩ Article dans une revue hal-03623326v1
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors Sotheara Moeung,Christine Chevreau,Sabrina Marsili,Christophe Massart,Aude Fléchonet al. Pharmaceutical Research, 2020, 37 (7), pp.147. ⟨10.1007/s11095-020-02861-5⟩ Article dans une revue hal-02935842v1
Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey Lorène Seguin,Rajae Touzani,Anne-Déborah Bouhnik,Ali Ben Charif,Patricia Marinoet al. Cancers, 2020, 12 (11), pp.3453. ⟨10.3390/cancers12113453⟩ Article dans une revue inserm-03192591v1
Essai GETUG/AFU-V05 VESPER phase III randomisée de chimiothérapie périopératoire (schéma MVAC dose-dense ou GC) dans le cancer de vessie infiltrant localisé. Résultats sur la toxicité de la chimiothérapie et la réponse histologique C. Pfister,G. Gravis,A. Flechon,M. Soulie,Laurent Guyet al. Progrès en Urologie, 2020, 30 (13), pp.715-716. ⟨10.1016/j.purol.2020.07.038⟩ Article dans une revue hal-02995801v1
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses Christian Pfister,Gwenaelle Gravis,Aude Fléchon,Michel Soulié,Laurent Guyet al. European Urology, 2020, ⟨10.1016/j.eururo.2020.08.024⟩ Article dans une revue hal-02995530v1
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial Sylvie Négrier,Nathalie Rioux-Leclercq,Céline Ferlay,Marine Gross-Goupil,Gwénaelle Graviset al. European Journal of Cancer, 2020, 129, pp.107 - 116. ⟨10.1016/j.ejca.2020.02.001⟩ Article dans une revue hal-02552562v1
Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring Sotheara Moeung,Christine Chevreau,Vianney Poinsignon,Jérôme Guitton,Bénédicte Lelièvreet al. Therapeutic Drug Monitoring, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩ Article dans une revue hal-02481351v1
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study Ronan Flippot,Cécile Dalban,Brigitte Laguerre,Delphine Borchiellini,Gwénaelle Graviset al. Journal of Clinical Oncology, 2019, 37 (23), pp.2008--2016. ⟨10.1200/JCO.18.02218⟩ Article dans une revue hal-02931819v1
Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men Rajae Touzani,Julien Mancini,Jaïs Troian,Anne-Déborah Bouhnik,Olivier Cussenotet al. Journal of Patient-Reported Outcomes, 2019, 3 (1), ⟨10.1186/s41687-019-0150-1⟩ Article dans une revue hal-02625852v1
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group Marine Sroussi,Reza Elaidi,Aude Fléchon,Marianne Lorcet,Delphine Borchielliniet al. Clinical Genitourinary Cancer, 2019, ⟨10.1016/j.clgc.2019.11.014⟩ Article dans une revue hal-02556645v1
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study Aline Guillot,Charlotte Joly,Philippe Barthélémy,Emeline Meriaux,Sylvie Négrieret al. Clinical Genitourinary Cancer, 2019, 17 (1), pp.e38-e43. ⟨10.1016/j.clgc.2018.08.006⟩ Article dans une revue istex hal-02420071v1
Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review Philippe Rochigneux,Jeanne Thomassin-Piana,Sophy Laibe,Serge Brunelle,Naji Salemet al. BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩ Article dans une revue hal-03689938v1
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer G. V. Long,S. S. Tykodi,J. G. Schneider,C. Garbe,G. Graviset al. Annals of Oncology, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩ Article dans une revue hal-02143540v1
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies Gwenaëlle Gravis,Jean-Marie Boher,Yu-Hui Chen,Glenn Liu,Karim Fizaziet al. European Urology, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩ Article dans une revue inserm-02092595v1
Gender difference in cancer survivors' perceived information 5-years after diagnosis: Data from the French national study - VICAN 5 G. Gravis,R. Touzani,A-D. Bouhnik,P. Marino,G. Pignotet al. Annals of Oncology, 2018, 29 (8) Article dans une revue hal-02143650v1
The role and use of Patient Reported Outcomes in the management of cancer patients Patricia Marino,Marie Bannier,Jean-François Moulin,Gwenaëlle Gravis Bulletin du Cancer, 2018, 105 (6), pp.603-609. ⟨10.1016/j.bulcan.2018.02.008⟩ Article dans une revue inserm-02096334v1
Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer Brice Chanez,Max Chaffanet,José Adélaide,Jeanne Thomassin,Séverine Garnieret al. JCO precision oncology, 2018, 2, pp.1-8. ⟨10.1200/po.18.00083⟩ Article dans une revue hal-03623699v1
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer Claudia S. E. W. Schuurhuizen,Patricia Marino,Annemarie M. J. Braamse,Laurien M. Buffart,Florence Jolyet al. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12), pp.1481-1488. ⟨10.6004/jnccn.2018.7069⟩ Article dans une revue hal-02143628v1
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma A. Mejean,A. Ravaud,S. Thezenas,S. Colas,J. -B. Beauvalet al. New England Journal of Medicine, 2018, 379 (5), pp.417-427. ⟨10.1056/NEJMoa1803675⟩ Article dans une revue hal-02143533v1
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen Gwenaelle Gravis,Emilien Billon,Capucine Baldini,Christophe Massard,Werner Hilgerset al. European Journal of Cancer, 2018, 104, pp.236-238. ⟨10.1016/j.ejca.2018.09.002⟩ Article dans une revue hal-02143638v1
Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study Sotheara Moeung,Christine Chevreau,Sophie Broutin,Jérome Guitton,Bénédicte Lelièvreet al. Clinical Cancer Research, 2017, 23 (23), pp.7171 - 7179. ⟨10.1158/1078-0432.CCR-17-1344⟩ Article dans une revue hal-01659726v1
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature Gwenaëlle Gravis,François Audenet,Jacques Irani,Marc-Olivier Timsit,Philippe Barthélémyet al. Cancer Treatment Reviews, 2017, 55, pp.211-217. ⟨10.1016/j.ctrv.2016.09.008⟩ Article dans une revue hal-01632557v1
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial P Lavaud,G Gravis,S Foulon,F Joly,S Oudardet al. European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩ Article dans une revue hal-01950269v1
Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? Damien Pouessel,Sylvie Chevret,Frédéric Rolland,Gwenaëlle Gravis,Lionel Geoffroiset al. European Journal of Cancer, 2016, 54, pp.69--74. ⟨10.1016/j.ejca.2015.11.017⟩ Article dans une revue istex hal-01278607v1
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma Nadine Houédé,Laura Dupuy,Aude Fléchon,Philippe Beuzeboc,Gwenaëlle Graviset al. BJU International, 2016, 117 (3), pp.444 - 449. ⟨10.1111/bju.13054⟩ Article dans une revue hal-01938234v1
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity Christine Pasero,Gwenaëlle Gravis,Mathilde Guerin,Samuel Granjeaud,Jeanne Thomassin-Pianaet al. Cancer Research, 2016, 76 (8), pp.2153-2165. ⟨10.1158/0008-5472.CAN-15-1965⟩ Article dans une revue hal-03599184v1
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Gwenaelle Gravis,Jean-Marie Boher,Florence Joly,Michel Soulié,Laurence Albigeset al. European Urology, 2016, 70, pp.256 - 262. ⟨10.1016/j.eururo.2015.11.005⟩ Article dans une revue inserm-03343628v1
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features Romain Mathieu,Géraldine Pignot,Alexandre Ingles,Maxime Crépel,Pierre Bigotet al. Urologic Oncology: Seminars and Original Investigations, 2015, 33 (8), pp.339.e9-339.e15. ⟨10.1016/j.urolonc.2015.05.014⟩ Article dans une revue hal-01260654v1
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model Gwenaelle Gravis,Jean-Marie Boher,Karim Fizazi,Florence Joly,Franck Priouet al. European Urology, 2015, 68 (2), pp.196 - 204. ⟨10.1016/j.eururo.2014.09.022⟩ Article dans une revue inserm-03353959v1
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Karim Fizazi,Laura Faivre,François Lesaunier,Remy Delva,Gwenaëlle Graviset al. Lancet Oncology, 2015, 16 (7), pp.787 - 794. ⟨10.1016/S1470-2045(15)00011-X⟩ Article dans une revue istex hal-01914904v1
A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma Elodie Jobard,Ellen Blanc,Sylvie Négrier,Bernard Escudier,Gwenaëlle Graviset al. British Journal of Cancer, 2015, 113 (8), pp.1148-1157. ⟨10.1038/bjc.2015.322⟩ Article dans une revue hal-01234309v1
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project A. Kramar,S. Negrier,R. Sylvester,S. Joniau,P. Mulderset al. Annals of Oncology, 2015, 26 (12), pp.2392-8. ⟨10.1093/annonc/mdv380⟩ Article dans une revue hal-01913181v1
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France Nadine Houédé,Philippe Beuzeboc,Sophie Gourgou,Diego Tosi,Laura Moiseet al. BMC Cancer, 2015, 15 (1), pp.222. ⟨10.1186/s12885-015-1257-2⟩ Article dans une revue inserm-01264474v1
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France. Nadine Houede,Philippe Beuzeboc,Sophie Gourgou,Diego Tosi,Laura Moiseet al. Journal of Clinical Oncology, 2015, 33 (7_suppl), pp.264-264. ⟨10.1200/jco.2015.33.7_suppl.264⟩ Article dans une revue hal-03578471v1
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis Benoit Beuselinck,Alexandra Karadimou,Diether Lambrechts,Bart Claes,Pascal Wolteret al. Acta Oncologica, 2014, 53 (1), pp.103--112. ⟨10.3109/0284186X.2013.770600⟩ Article dans une revue hal-01064635v1
Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Gwenaëlle Gravis,Patricia Marino,Florence Joly,Stéphane Oudard,Franck Priouet al. European Journal of Cancer, 2014, pp.953 - 962. ⟨10.1016/j.ejca.2013.11.034⟩ Article dans une revue istex hal-01917876v1
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial K. Fizazi,G. Gravis,Aude Flechon,L. Geoffrois,C. Chevreauet al. Annals of Oncology, 2014, 25, pp.987--91. ⟨10.1093/annonc/mdu099⟩ Article dans une revue hal-02168058v1
FGFR1 and WT1 are markers of human prostate cancer progression. Elizabeth Devilard,Franck Bladou,Olivier Ramuz,Gilles Karsenty,Jean-Philippe Dalèset al. BMC Cancer, 2006, 6, pp.272. ⟨10.1186/1471-2407-6-272⟩ Article dans une revue inserm-00121110v1
Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens D. Genre,P. Viens,F. Bertucci,C Chabannon,G. Graviset al. Bone Marrow Transplantation, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩ Article dans une revue inserm-03199676v1
Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles Dominique Genre,C. Protière,Geneviève Macquart-Moulin,G. Gravis,Jacques Camerloet al. Supportive Care in Cancer, 2002, 10 (3), pp.222-230. ⟨10.1007/s00520-001-0322-3⟩ Article dans une revue istex inserm-03199677v1
Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Patrice Viens,Dominique Genre,Christel Protiere,Gwenaelle Gravis,François Bertucciet al. European Cytokine Network, 1998, 9 (1), pp.93-98 Article dans une revue inserm-04975072v1

Communication dans un congrès (3)

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 S. Gillessen,Alberto Bossi,Ian D. Davis,Johann Sebastian de Bono,Karim S. Fizaziet al. unknow, 2023, unknow, France. pp.178-215, ⟨10.1016/j.ejca.2023.02.018⟩ Communication dans un congrès hal-04107713v1
Analyse en vie réelle des séquences de traitement de patients initiant de l&#039;abiratérone et de l&#039;enzalutamide pour un cancer de prostate résistant à la castration métastatique L. M. Scailteux,S. Vincendeau,G. Gravis,F. Balusson,R Mathieuet al. Congrès EMOIS 2023, Mar 2023, Nancy, France. pp.101430-101430, ⟨10.1016/j.respe.2023.101430⟩ Communication dans un congrès hal-04284910v1
A non-inferiority randomized phase III trial of standard immunotherapy versusreduced dose intensity in responding patients with metastatic cancer: MOIO study. Gwenaelle Gravis,Daniel Olive,Patricia Marino,Frederique Madeleine Penault-Llorca,Jean-Pierre Delordet al. ASCO, 2022, Chicago, United States. pp.TPS2674, ⟨10.1200/JCO.2022.40.16_suppl.TPS2674⟩ Communication dans un congrès hal-03929783v1